Available online www.ijpras.com

International Journal of Pharmaceutical Research & Allied Sciences, 2025, 14(4):1-13
https://doi.org/10.51847/Z5IOypbB4U

Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through Reproducibility, Manufacturing Feasibility, Biological Validation, and Clinical Relevance

Ethan Wright[1]*, Chloe Bennett[2], Jack Turner[1], Olivia Harris[3]

[1]*Department of Translation Readiness and Dossier Management, Faculty of Pharmacy, University of Leeds, Leeds, United Kingdom.*
[2]*Department of Manufacturing Feasibility and Biological Validation, Faculty of Pharmacy, University of Sheffield, Sheffield, United Kingdom.*
[3]*Department of Clinical Relevance and Evidence Tracking, Faculty of Pharmacy, University of York, York, United Kingdom.*

***Email:** ethan.wright@leeds.ac.uk*

ABSTRACT

Pharmaceutical concepts commonly advance through discovery and development by completing predefined activities, entering formal phases, or satisfying locally defined technical milestones. These events are operationally useful but do not necessarily demonstrate that the supporting evidence is reproducible, biologically relevant, manufacturable, clinically interpretable, or adequate for the next consequential decision. This Original Translation-Readiness Architecture Article proposes a Translation-Readiness Dossier for organizing evidence around a defined pharmaceutical concept and intended therapeutic use. The architecture separates foundational robustness, biological validation, manufacturing feasibility, safety and pharmacology, clinical relevance, uncertainty, and implementation requirements rather than compressing them into a single maturity label. Each domain is linked to evidence provenance, context of use, unresolved assumptions, and explicit decision boundaries. Safety, pharmacology, and clinical relevance are treated as related but non-equivalent evidence dimensions, preventing mechanistic plausibility, favorable model output, or technical performance from being interpreted automatically as patient-relevant readiness. Evidence gaps are retained visibly, while proposed readiness grades describe domain-specific evidentiary states without functioning as validated scores or predictions of success. Reversible decision gates allow progression, conditional progression, additional evidence generation, redesign, hold, or termination, and a version-controlled updating process records how new findings alter previous assumptions. The original contribution is an integrated, non-compensatory architecture intended to improve traceability and expose cross-domain discordance. Its value requires prospective evaluation of reliability, feasibility, resistance to selective reporting, inter-rater consistency, and consequences for real development decisions. The dossier is not a regulatory submission, clinical recommendation, validated predictive instrument, or universally applicable deployment standard.

Key words: *Translational pharmaceutical research, Translation readiness, Reproducibility, Manufacturing feasibility, Clinical relevance, Evidence maturity*

Received: 25 May 2025; **Revised:** 06 October 2025; **Accepted:** 10 October 2025

INTRODUCTION

Pharmaceutical development is conventionally represented as movement through discovery stages, candidate nomination, preclinical testing, clinical phases, manufacturing transitions, and regulatory review. Such progression records completed activities but does not necessarily establish whether a concept possesses evidence

that is predictive, transferable, and adequate for the decision being made. Clinical-development outcomes vary across phases and therapeutic contexts, while failure may arise from efficacy, safety, pharmacology, study design, manufacturing, or strategic limitations [1-3].

This distinction matters because a concept can appear advanced while remaining dependent on fragile experiments, incompletely characterized mechanisms, untested scale assumptions, or models with uncertain relevance to patients. Conversely, an early concept may possess unusually strong human biological support or manufacturing knowledge despite having crossed few formal milestones. Development stage and translation readiness are therefore related but non-equivalent descriptions.

Translation readiness is defined here as the degree to which traceable evidence supports a specified next decision for a defined pharmaceutical concept and intended therapeutic use. It is narrower than translation as a general movement from research to health impact, broader than technical feasibility alone, and distinct from regulatory readiness. It also differs from evidence maturity when maturity is treated only as the volume or age of accumulated information rather than its reproducibility, relevance, coherence, and decision suitability.

This article develops an original, non-empirical Translation-Readiness Dossier architecture. The proposed contribution integrates concept definition, evidence provenance, foundational robustness, biological validation, manufacturing feasibility, safety, pharmacology, clinical relevance, uncertainty, decision gates, and updating. It organizes questions that should be evaluated rather than claiming that the architecture has been validated, that its use improves development outcomes, or that one configuration can apply unchanged across products, modalities, organizations, and therapeutic areas.

Why conventional development milestones inadequately represent readiness

Development milestones inadequately represent readiness when they indicate that an activity occurred without showing whether the resulting evidence supports a consequential inference. Historical effectiveness differs across therapeutic mechanisms and indications, multidimensional assessment frameworks reveal weaknesses not captured by stage labels, and changes in portfolio and decision practices can accompany changes in development outcomes [4-6]. These findings support closer examination of evidence states, although they do not establish one universal explanation for pharmaceutical attrition.

A milestone may record target selection, lead nomination, completion of an animal study, production of a pilot batch, or entry into a clinical phase. None of these events independently establishes that the target is causal in the intended population, that the result can be reproduced, that the product can be manufactured consistently, or that the measured effect is clinically meaningful. Milestones describe progression through an organized process; readiness concerns the adequacy of evidence for a specified decision.

The limitation becomes more important when domains develop asynchronously. Strong biological activity may coexist with unstable material properties, while scalable production may coexist with weak human-mechanistic support. A favorable model may depend on an exposure range that cannot be achieved safely, and a reproducible assay may measure an endpoint with little relevance to the intended therapeutic effect. A linear milestone narrative can conceal these disagreements by presenting advancement in one domain as evidence of advancement in all others.

Figure 1 presents the original conceptual synthesis for translation-readiness dossier architecture, showing how the article's principal components, evidence relationships, uncertainties, and decision boundaries are connected.



Figure 1. Translation-Readiness Dossier Architecture.

The figure is an original conceptual synthesis developed for "A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through Reproducibility, Manufacturing Feasibility, Biological Validation, and Clinical Relevance." Arrows and grouping indicate proposed or evidence-supported relationships rather than measured effect sizes. The figure does not represent a validated predictive model, clinical recommendation, regulatory determination, or deployment-ready system.

The architecture therefore rejects automatic compensation across domains. Additional mechanistic evidence cannot by itself resolve an uncontrolled manufacturing process, and manufacturing consistency cannot establish clinical value. This non-compensatory interpretation is proposed rather than empirically demonstrated. Its purpose is to make critical deficiencies visible and to require an explicit rationale whenever progression is permitted despite them.

Alternative explanations must also remain visible. Attrition may reflect financing, portfolio strategy, competitive change, recruitment difficulty, commercial priorities, or organizational capability rather than a scientific deficiency alone. The dossier is not intended to reduce every discontinuation to inadequate evidence. It instead asks whether the evidence supporting a scientific or technical progression decision was sufficiently relevant, reproducible, and complete for that specific decision.

Proposed translation-readiness dossier

The proposed Translation-Readiness Dossier is a living, version-controlled record that connects a pharmaceutical concept to its intended use, supporting evidence, unresolved assumptions, and decision history. Structured target-assessment approaches demonstrate the value of making evidence categories and decision questions explicit rather than relying on an undifferentiated narrative of promise [7]. The dossier extends this logic beyond target assessment to include experimental robustness, product realization, safety, pharmacology, patient relevance, and implementation.

The architecture contains a stable identification layer, modular evidence records, domain-specific judgements, an uncertainty register, and a decision-and-update layer. The identification layer defines what is being evaluated. Evidence modules record what is known, how it was established, and within which context it is interpretable. Domain judgements describe whether the available evidence is adequate for a stated decision, while the update layer preserves changes in evidence, assumptions, intended use, and gate outcomes.

Evidence provenance is essential because identical claims can have different implications depending on the method, model, analyst, laboratory, material batch, protocol version, comparator, and degree of independence.

Research-quality systems support documentation, predefined responsibilities, quality controls, risk management, and continuous improvement in preclinical work [8]. These principles inform the dossier's provenance fields, but their inclusion does not establish that the proposed architecture will improve translation.

The dossier also distinguishes scientific outputs from translational consequences. Frameworks for translational science have shown that benefits can be organized across multiple domains rather than inferred from publications or procedural completion alone [9]. In the proposed architecture, biological evidence, manufacturing evidence, clinical relevance, and implementation feasibility remain separately inspectable because progress in one category may not transfer to another.

The central decision rule is therefore conditional adequacy rather than generalized maturity. A concept may be sufficiently supported for exploratory mechanism testing but not for scale investment, first-in-human exposure, or comparative clinical evaluation. Each judgement must identify the decision to which it applies, the evidence considered, the principal uncertainties, and the conditions under which it should be revised. The dossier does not replace a regulatory dossier, target product profile, quality system, development plan, or clinical protocol.

Concept definition and intended therapeutic use

The dossier begins with a precise definition of the pharmaceutical concept. Depending on development context, the concept may be a target–disease hypothesis, molecular intervention, formulation, delivery system, engineered cell, diagnostic–therapeutic combination, manufacturing platform, or integrated product–device configuration. Definition should include the active principle, proposed mechanism, product form, route, regimen, development stage, and features that distinguish the concept from related alternatives.

Intended therapeutic use provides the reference against which evidence relevance is judged. It should identify the indication, patient population, disease stage, treatment setting, comparator, intended benefit, administration conditions, and major patient-facing requirements. Pharmaceutical product attributes, device features, handling requirements, dosing flexibility, and use conditions can materially affect whether a technically feasible product is appropriate for patients [10]. Intended use must therefore encompass product and administration realities rather than mechanism alone.

Experimental-model relevance is likewise conditional on the intended question. Human organ-on-chip systems may model selected tissue functions, disease processes, exposures, or patient-specific responses, but their value depends on the biological features represented and the inference sought [11]. Evidence generated in a sophisticated human-derived system should not be considered intrinsically more decisive when the system omits a mechanism, exposure pattern, immune interaction, or clinical context essential to the proposed use.

Platform readiness must also be separated from application readiness. Organ-on-chip technologies illustrate how standardization, reproducibility, qualification, and compatibility with development workflows remain context-dependent even when the broader platform is scientifically promising [12]. The dossier therefore requires a change-control rule: when the indication, population, formulation, route, dose, comparator, manufacturing process, or intended decision changes materially, prior evidence must be re-examined rather than transferred automatically. A well-defined intended use improves the interpretability of evidence but does not demonstrate that the concept can achieve the intended clinical outcome.

Reproducibility and robustness of foundational evidence

Reproducibility is not a single property. It includes the ability to reconstruct an analysis, repeat a procedure under comparable conditions, reproduce a biological effect, obtain consistent results across operators or sites, and replicate a central finding independently. Transparent methods, complete reporting, and direct replication address different sources of uncertainty and should not be compressed into a binary reproducibility designation [13-15].

The dossier therefore records protocol versions, materials, analytical procedures, inclusion and exclusion rules, controls, randomization and blinding where applicable, missing-data handling, code and data availability, and deviations from prespecified plans. Reporting completeness is necessary for assessment but does not prove that the experiment was well designed or that the reported finding is correct. Likewise, exact computational reproduction can regenerate an output while preserving invalid assumptions.

Robustness concerns whether a claim remains materially stable under reasonable variations in experimental conditions, model specification, reagent source, analytical method, manufacturing input, or population. The proposed dossier separates robustness from replication because a finding may reproduce under narrowly identical conditions yet fail when transferred to another laboratory, model, batch, or clinically relevant exposure. Negative and discordant findings are retained rather than summarized away.

A foundational-evidence profile should therefore specify what was reproduced, by whom, under which conditions, and for which inference. It should also identify dependencies that make the result fragile or non-transferable. **Table 1** organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for definitions, components, relationships, and intended uses in a translation readiness dossier for tracking pharmaceutical concepts through.

Table 1. Definitions, components, relationships, and intended uses in A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through.

Component or scientific dimension	Problem addressed	Inputs or determinants	Proposed mechanism or relationship	Expected contribution	Evidence required	Failure or uncertainty risk	Boundary statement
Concept identity	Ambiguous or changing object of assessment	Intervention, target, product form, route, mechanism	**Proposed:** fixes the unit being tracked before readiness is judged	Improves traceability	Versioned definition and change history	Evidence may be combined across materially different concepts	Definition does not establish feasibility
Intended therapeutic use	Evidence may be irrelevant to the actual patient or decision	Indication, population, comparator, setting, regimen, patient-facing requirements [10]	**Proposed:** determines which evidence is decision-relevant	Prevents context-free readiness claims	Explicit intended-use statement	Intended use may change during development	Intended use does not establish benefit
Evidence provenance	Claims may be detached from their methods and limitations	Protocol, model, material, site, analyst, version, independence [8]	**Proposed:** links each claim to its evidentiary origin	Supports auditability and updating	Accessible records and quality controls	Selective documentation or inaccessible proprietary evidence	Traceability does not validate the claim
Foundational reproducibility	Initial findings may be unstable or incompletely reported	Methods, controls, reporting, repeatability, replication [14]	**Proposed:** separates reconstruction, repetition, robustness, and replication	Clarifies confidence in foundational evidence	Prespecified methods and independent confirmation where proportionate	Exact repetition may preserve systematic bias	Reproducibility does not establish biological relevance
Biological validation	Activity may be mistaken for causal or human relevance	Causal evidence, target engagement, model relevance, human concordance	**Proposed:** links mechanism claims to defined biological questions	Exposes inferential gaps	Orthogonal and context-relevant evidence	Association, model mismatch, or unsupported extrapolation	Biological support does not prove clinical benefit
Manufacturing feasibility	Laboratory success may not survive scale or control requirements	Materials, process parameters, quality attributes, scale, comparability [16]	**Proposed:** treats product realization as an independent domain	Identifies process-limiting assumptions early	Scale-relevant process and quality evidence	Material variability, instability, or uncontrolled process interactions	Feasibility does not equal process validation
Safety and pharmacology	Mechanistic promise may coexist with unacceptable	Exposure, target distribution, off-target effects, dose,	**Proposed:** connects mechanism and exposure to	Improves interpretation of progression decisions	Nonclinical, model-informed, and human-relevant	Unknown exposure-response relationships or	The dossier cannot establish clinical safety

	exposure or hazard	duration, safety signals	bounded risk questions		evidence as applicable	unmeasured hazards	
Clinical and patient relevance	Surrogate or technical performance may lack patient meaning	Endpoints, biomarkers, usability, adherence burden, comparator, benefit–risk	**Proposed:** distinguishes patient relevance from technical readiness	Prevents premature clinical interpretation	Clinically interpretable and use-relevant evidence	Endpoint mismatch or unrepresentative populations	Relevance does not establish efficacy
Uncertainty and discordance register	Conflicting or absent evidence may be hidden	Missing studies, inconsistent findings, transfer assumptions	**Proposed:** prevents unresolved uncertainty from disappearing into a summary grade	Makes conditionality visible	Documented gaps and competing explanations	Strategic omission or false reassurance	Uncertainty recording does not resolve uncertainty
Decision and update record	Decisions may become detached from changing evidence	Gate outcome, rationale, conditions, version, new findings	**Proposed:** makes progression reversible and reviewable	Supports institutional learning	Dated decisions and explicit reopening triggers	Stale records or retrospective rationalization	Documentation does not prove decision quality

Biological validation and mechanism relevance

Biological validation should determine whether the proposed mechanism is causally relevant to the intended disease, population, exposure, and therapeutic intervention. Human genetic support may strengthen target assessment, but its association with development success depends on how genetic support, mechanism, and approval are defined [17]. Genetic evidence should therefore modify, not replace, experimental and pharmacological validation.

Safety-related phenotypes associated with genes encoding drug targets may help anticipate mechanism-linked adverse effects [18]. Such evidence is valuable because it can reveal consequences of perturbing the same biological system in humans. However, lifelong genetic variation differs from time-limited pharmacological modulation in magnitude, timing, tissue distribution, and reversibility.

Human-relevant experimental systems may provide evidence unavailable from conventional models. A Liver-Chip reproduced selected human and cross-species toxicities under defined experimental conditions [19]. This supports the use of engineered human models for bounded questions but does not establish that one model predicts all toxicities, populations, doses, or clinical outcomes.

The dossier consequently separates causal support, target engagement, pathway modulation, disease-model relevance, cross-model concordance, and human relevance. Advancement requires an explanation of how each evidence type addresses the intended mechanism and where inference remains indirect. No single genetic, cellular, animal, or engineered-tissue result is treated as sufficient evidence of patient benefit.

Manufacturability, scalability, and quality control

Manufacturing readiness concerns whether the proposed product can be produced with controlled attributes under conditions relevant to later development. Continuous-manufacturing experience illustrates that process integration, material flow, monitoring, control strategy, and regulatory-science considerations must be addressed when moving from theory to practice [16]. A successful laboratory preparation is therefore evidence of possibility, not necessarily of scalable control.

Scale can alter mixing, heat and mass transfer, residence-time behavior, material stress, and process variability. Reviews of continuous oral-solid manufacturing show that equipment integration and process control create challenges not represented by isolated unit-operation success [20]. The dossier should identify which scale assumptions have been examined and which remain extrapolations.

Quality control should be linked to product and process understanding rather than treated only as final-product testing. A knowledge- and risk-based pharmaceutical-quality approach emphasizes lifecycle learning and control

[21]. Within the proposed architecture, critical material attributes, process parameters, quality attributes, analytical capability, stability, comparability, and supply dependencies are recorded as separate evidence fields.

Manufacturing deficiencies are non-compensatory when they prevent production of a product suitable for the intended evidence-generating step. The architecture does not prescribe universal thresholds because requirements differ across small molecules, biologics, cell therapies, delivery systems, and combination products. **Table 2** organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for testable propositions, evidence requirements, and validation criteria for a translation readiness dossier for tracking pharmaceutical concepts through.

Table 2. Testable propositions, evidence requirements, and validation criteria for A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through.

Architecture layer or process stage	Core function	Information or material flow	Interaction with other components	Validation criterion	Potential failure mode	Human or experimental responsibility	Readiness boundary
Intended-use anchor	Defines the decision and patient context	Intended use flows to every evidence module	Determines relevance of models, product attributes, and endpoints	**Proposed criterion:** independent reviewers identify the same decision context	Vague or shifting intended use	Multidisciplinary team defines and approves changes	Clear definition does not establish readiness
Provenance layer	Preserves origin and limitations of evidence	Methods, versions, models, materials, and deviations accompany each claim	Enables audit and reinterpretation	**Proposed criterion:** key claims can be reconstructed from the record	Missing, selective, or incompatible records	Investigators and quality personnel maintain traceability	Provenance does not establish validity
Reproducibility module	Tests stability of foundational evidence	Results move from repetition to robustness and independent replication	Informs biological and decision confidence	**Proposed criterion:** prespecified central claims are reproducible under relevant conditions	Reproduction of an artefact or laboratory-specific effect	Independent experimental and analytical teams	Reproducibility does not prove mechanism
Biological-validation module	Evaluates causal and human relevance	Mechanistic evidence moves across models and perturbations	Interacts with safety and pharmacology	**Proposed criterion:** orthogonal evidence supports the intended causal chain	Association interpreted as causation	Domain specialists design mechanism-relevant tests	Mechanism support does not prove benefit
Manufacturing module	Tests product realization and control	Materials pass through scale-relevant processes to defined quality attributes	Constrains exposure, stability, and clinical use	**Proposed criterion:** process variability remains detectable and controllable for the intended stage	Scale-dependent drift or inadequate analytical control	Process, analytical, formulation, and quality teams	Feasibility is not process validation

Safety and pharmacology module	Relates intervention and exposure to benefit–risk questions	Dose, exposure, distribution, response, and hazard evidence are integrated	Connects biological mechanism to clinical relevance	**Proposed criterion:** major exposure and mechanism assumptions are tested within a defined context	Unsupported extrapolation across dose, duration, or population	Pharmacology, toxicology, modeling, and clinical experts	Evidence does not constitute a safety determination
Uncertainty layer	Preserves gaps, disagreement, and transfer assumptions	Uncertainty accompanies all domain judgements	Prevents unconditional progression claims	**Proposed criterion:** material uncertainty changes the gate rationale or evidence plan	Cosmetic uncertainty statements with no decision effect	Reviewers challenge assumptions and alternatives	Recorded uncertainty is not resolved uncertainty
Decision gate	Converts evidence into a reversible action	Domain judgements and unresolved risks enter the gate	Produces progress, conditional progress, hold, redesign, repeat, or stop	**Proposed criterion:** gate outcomes are reproducible and prospectively reviewable	Dominance by schedule, hierarchy, or one favorable domain	Accountable multidisciplinary decision body	A gate outcome is not regulatory authorization

Safety, pharmacology, and clinical relevance

Safety readiness requires more than an absence of observed toxicity in a limited model. Human genetics can contribute to therapeutic safety assessment by revealing phenotypic consequences associated with perturbation of relevant genes, while retaining limitations related to exposure, timing, and causal interpretation [22]. The dossier records whether safety evidence addresses the intended target, modality, route, duration, and population.

Pharmacological readiness concerns whether exposure, distribution, target engagement, and response are connected sufficiently for the intended decision. Model-informed drug development requires documentation of assumptions, data, methods, qualification, and decision context [23]. A model suitable for compound ranking may therefore be inadequate for dose selection, safety extrapolation, or prediction in a different population.

Clinical relevance concerns whether the evidence addresses outcomes, biomarkers, comparators, administration conditions, and patient experiences that matter to the proposed use. Human liver microtissues have been evaluated against compounds with known clinical drug-induced liver-injury outcomes, illustrating how a model can be benchmarked against a defined clinical consequence [24]. Performance in one endpoint and organ context cannot be generalized automatically.

The dossier integrates safety, pharmacology, and clinical relevance while preserving their distinctions. Favorable exposure does not establish efficacy, absence of a model signal does not establish safety, and a biomarker response does not establish patient benefit. The resulting profile supports a bounded progression discussion rather than a clinical recommendation or authorization for human use.

Evidence gaps, uncertainty, and readiness grading

Readiness assessment should expose what remains unknown rather than reward the volume of accumulated evidence. A model's required credibility depends on its context of use and the consequence of an incorrect decision [25]. The same principle is proposed for experimental, manufacturing, and clinical claims: evidentiary demands should increase with the consequence and irreversibility of the decision.

Verification, validation, uncertainty assessment, and applicability answer different questions in mechanistic model evaluation [26]. The dossier extends this separation across domains. Verification asks whether a procedure was implemented correctly; validation asks whether it performs adequately against relevant evidence; applicability asks whether that evidence supports the intended use; uncertainty records the remaining limits.

Five qualitative domain states are proposed: unsupported, exploratory, corroborated, decision-adequate for a defined use, and externally evaluated. These are descriptors rather than numerical scores. A state applies only to a named domain, claim, and decision and should not be interpreted as a universal property of the concept.

A non-compensatory rule is proposed for critical deficiencies. A concept cannot be considered ready for a decision when a necessary domain remains unsupported merely because another domain is strong. Conditional progression may still be justified, but the unresolved deficiency, rationale, safeguards, and required next evidence must be recorded explicitly.

Readiness grades require empirical evaluation before operational use. Relevant studies should assess inter-rater agreement, sensitivity to missing or discordant evidence, prospective stability, burden, susceptibility to strategic presentation, and association with decision quality without assuming that later technical or clinical success is the only valid outcome. **Table 3** organizes the evidence, constructs, relationships, uncertainties, and boundary conditions required for failure modes, boundary conditions, governance needs, and implementation priorities for a translation readiness dossier for tracking pharmaceutical concepts through.

Table 3. Failure modes, boundary conditions, governance needs, and implementation priorities for A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through.

Decision scenario or design trade-off	Trigger or context	Competing objective	Evidence threshold	Uncertainty treatment	Corrective or escalation action	Expected implication	What cannot be concluded
Progress despite incomplete evidence	Time pressure or high perceived opportunity	Speed versus evidentiary sufficiency	**Proposed:** necessary domains must be at least decision-adequate for the stated action	Unresolved gaps remain visible and conditional	Conditional progress with defined safeguards and evidence plan	Preserves momentum without erasing risk	Progress does not establish success
Strong biology but weak reproducibility	Compelling mechanism from fragile studies	Novelty versus reliability	**Proposed:** central findings require proportionate independent confirmation	Treat laboratory dependence as material uncertainty	Repeat, redesign, or obtain orthogonal evidence	Reduces reliance on a single evidentiary chain	Replication alone does not prove clinical relevance
Strong mechanism but weak manufacturability	Product cannot be produced consistently	Scientific promise versus product realization	**Proposed:** scale-relevant feasibility for the intended stage	Record process and material assumptions	Formulation or process redesign; consider alternative modality	Prevents technical promise from concealing product failure	Feasibility does not prove commercial supply
Favorable model output with uncertain applicability	Model used outside its supported domain	Decision efficiency versus model credibility	Context-specific credibility proportionate to consequence [25]	Separate model uncertainty from biological uncertainty	Restrict use, generate validation evidence, or use alternative models	Limits extrapolation beyond evidence	A credible model is not regulator-approved
Discordant safety evidence	Genetic, experimental, or model findings conflict	Progression versus precaution	**Proposed:** no universal threshold; consequence and plausibility govern escalation	Preserve competing explanations	Independent review and targeted evidence generation	Prevents selective reliance on favorable findings	Discordance does not prove toxicity
Readiness-grade disagreement	Reviewers interpret	Consistency versus expert judgement	**Proposed:** prespecified definitions and	Treat disagreement	Adjudication, calibration,	Tests usability and reliability	Consensus does not

	evidence differently		documented rationale	as information	and revision of definitions		prove correctness
Automated evidence generation	High-throughput or autonomous experiments update the record	Efficiency versus oversight	**Proposed:** validated methods and bounded experimental authority	Record algorithmic and experimental limitations	Human review before gate modification	Accelerates evidence generation while retaining accountability	Automation cannot authorize clinical progression
Stale dossier	New evidence or intended-use change	Continuity versus current validity	**Proposed:** material changes trigger reassessment	Prior judgements remain versioned, not overwritten	Reopen affected gates	Maintains traceable decision history	Updating does not ensure a better decision
Organizational implementation	Dossier adopted across teams or sites	Standardization versus local context	**Proposed:** prospective feasibility and reliability evidence	Record workflow, access, and incentive effects	Pilot, audit, revise, or withdraw	Identifies burden and unintended consequences	Adoption does not establish effectiveness

Decision gates and dossier updating

A decision gate converts domain evidence into an explicit, reversible action. The proposed outcomes are progress, conditional progress, generate evidence, redesign, hold, or stop. Each outcome must identify the intended decision, critical evidence, dissenting interpretation, unresolved uncertainty, accountable decision makers, and conditions that would reopen the gate.

Autonomous experimentation shows that systems can select and execute experiments iteratively within bounded problem spaces. A mobile robotic chemist demonstrated closed-loop experimental operation in a defined materials context [27]. An automated synthesis platform similarly used machine learning to explore reaction space and update experimental choices [28]. These studies support iterative evidence generation, not autonomous authority over pharmaceutical or clinical progression.

Figure 2 presents the original conceptual synthesis for evidence-gated progression from concept to patient-relevant readiness, showing how the article's principal components, evidence relationships, uncertainties, and decision boundaries are connected.



Figure 2. Evidence-Gated Progression from Concept to Patient-Relevant Readiness.

The figure is an original conceptual synthesis developed for "A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through Reproducibility, Manufacturing Feasibility, Biological Validation, and Clinical

Relevance." Arrows and grouping indicate proposed or evidence-supported relationships rather than measured effect sizes. The figure does not represent a validated predictive model, clinical recommendation, regulatory determination, or deployment-ready system.

Dossier updating is triggered when new evidence changes a material claim, uncertainty, or intended use. Updates may follow independent replication, altered formulation, process failure, safety findings, exposure data, population changes, or evidence that a model no longer represents the required context. Previous versions remain accessible so that changing decisions can be distinguished from retrospective rewriting.

Automation may populate fields, detect inconsistencies, or propose experiments, but governance authority remains human and multidisciplinary. The architecture requires review of evidence provenance, assumptions, conflicts of interest, and consequences before a gate changes. Iterative updating is intended to support learning; it does not guarantee that the revised judgement is correct.

Limitations and implementation requirements

The architecture may be difficult to standardize across modalities, organizations, and stages. Evidence sufficient for exploratory chemistry differs from evidence required for a biologic, engineered cell, implant, or first-in-human decision. Domain definitions must therefore remain consistent enough for audit while allowing justified adaptation.

Implementation can fail even when a framework is conceptually coherent. The NASSS framework shows that adoption does not establish scale-up, spread, sustainability, or freedom from abandonment [29]. A dossier could become an administrative exercise, duplicate existing systems, privilege well-resourced programs, or create false reassurance through formal completion.

Evaluation should account for context, system interactions, implementation processes, and change over time, as emphasized in updated guidance for complex interventions [30]. Initial testing should examine usability, reviewer calibration, access to evidence, updating burden, unintended incentives, and effects on disagreement. Comparisons with current decision practices should be prospective and should include cases in which the dossier recommends delay, redesign, or discontinuation.

Governance requirements include accountable ownership, access control, audit trails, conflict-of-interest disclosure, version control, scheduled review, protection of negative evidence, and mechanisms for challenge and appeal. The dossier should not be mandated as a universal standard until its reliability, fairness, burden, resistance to gaming, and decision consequences have been evaluated.

CONCLUSION

The proposed Translation-Readiness Dossier reframes pharmaceutical progression as a decision-specific assessment of reproducibility, biological validity, manufacturing feasibility, safety, pharmacology, clinical relevance, uncertainty, and implementation conditions. Its central contribution is a living, evidence-traceable and non-compensatory architecture that preserves cross-domain disagreement, makes assumptions visible, and supports reversible decision gates. The framework does not convert conceptual plausibility into empirical validation, technical feasibility into clinical benefit, or organizational adoption into regulatory acceptance. Prospective evaluation is required before it can be considered a reliable or useful decision instrument.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Scannell JW, Bosley J, Hickman JA, Dawson GR, Truebel H, Ferreira GS, et al. Predictive validity in drug discovery: What it is, why it matters and how to improve it. Nat Rev Drug Discov. 2022;21(12):915-31. doi:10.1038/s41573-022-00552-x

2. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-86. doi:10.1093/biostatistics/kxx069
3. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049-62. doi:10.1016/j.apsb.2022.02.002
4. Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov. 2018;17(1):19-33. doi:10.1038/nrd.2017.194
5. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17(3):167-81. doi:10.1038/nrd.2017.244
6. Wu SS, Fernando K, Allerton C, Jansen KU, Vincent MS, Dolsten M. Reviving an R&D pipeline: A step change in the Phase II success rate. Drug Discov Today. 2021;26(2):308-14. doi:10.1016/j.drudis.2020.10.019
7. Emmerich CH, Gamboa LM, Hofmann MCJ, Bonin-Andresen M, Arbach O, Schendel P, et al. Improving target assessment in biomedical research: The GOT-IT recommendations. Nat Rev Drug Discov. 2021;20(1):64-81. doi:10.1038/s41573-020-0087-3
8. Bespalov A, Bernard R, Gilis A, Gerlach B, Guillén J, Castagné V, et al. Introduction to the EQIPD quality system. Elife. 2021;10. doi:10.7554/eLife.63294
9. Luke DA, Sarli CC, Suiter AM, Carothers BJ, Combs TB, Allen JL, et al. The Translational Science Benefits Model: A new framework for assessing the health and societal benefits of clinical and translational sciences. Clin Transl Sci. 2018;11(1):77-84. doi:10.1111/cts.12495
10. Algorri M, Abernathy MJ, Cauchon NS, Christian TR, Lamm CF, Moore CMV. Patient-centric product development: A summary of select regulatory CMC and device considerations. J Pharm Sci. 2023;112(4):922-36. doi:10.1016/j.xphs.2023.01.029
11. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467-91. doi:10.1038/s41576-022-00466-9
12. Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. Organs-on-chips: Into the next decade. Nat Rev Drug Discov. 2021;20(5):345-61. doi:10.1038/s41573-020-0079-3
13. Munafò MR, Nosek BA, Bishop DVM, Button KS, Chambers CD, Percie du Sert N, et al. A manifesto for reproducible science. Nat Hum Behav. 2017;1(1):0021. doi:10.1038/s41562-016-0021
14. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7). doi:10.1371/journal.pbio.3000410
15. Errington TM, Mathur M, Soderberg CK, Denis A, Perfito N, Iorns E, et al. Investigating the replicability of preclinical cancer biology. Elife. 2021;10. doi:10.7554/eLife.71601
16. Nasr MM, Krumme M, Matsuda Y, Trout BL, Badman C, Mascia S, et al. Regulatory perspectives on continuous pharmaceutical manufacturing: Moving from theory to practice. J Pharm Sci. 2017;106(11):3199-206. doi:10.1016/j.xphs.2017.06.015
17. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15(12). doi:10.1371/journal.pgen.1008489
18. Nguyen PA, Born DA, Deaton AM, Nioi P, Ward LD. Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. Nat Commun. 2019;10(1):1579. doi:10.1038/s41467-019-09407-3
19. Jang KJ, Otieno MA, Ronxhi J, Lim HK, Ewart L, Kodella KR, et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci Transl Med. 2019;11(517). doi:10.1126/scitranslmed.aax5516
20. Vanhoorne V, Vervaet C. Recent progress in continuous manufacturing of oral solid dosage forms. Int J Pharm. 2020;579:119194. doi:10.1016/j.ijpharm.2020.119194
21. Yu LX, Kopcha M. The future of pharmaceutical quality and the path to get there. Int J Pharm. 2017;528(1-2):354-9. doi:10.1016/j.ijpharm.2017.06.039
22. Walker VM, Davey Smith G, Davies NM, Martin RM. Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discov. 2023;22(2):145-62. doi:10.1038/s41573-022-00561-w
23. Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, et al. Model-informed drug discovery and development: Current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol. 2019;8(2):87-96. doi:10.1002/psp4.12372

24. Proctor WR, Foster AJ, Vogt J, Summers C, Middleton B, Pilling MA, et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol. 2017;91(8):2849-63. doi:10.1007/s00204-017-2002-1
25. Kuemmel C, Yang Y, Zhang X, Florian J, Zhu H, Tegenge M, et al. Consideration of a credibility assessment framework in model-informed drug development: Potential application to physiologically-based pharmacokinetic modeling and simulation. CPT Pharmacometrics Syst Pharmacol. 2020;9(1):21-8. doi:10.1002/psp4.12479
26. Musuamba FT, Skottheim Rusten I, Lesage R, Russo G, Bursi R, Emili L, et al. Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):804-25. doi:10.1002/psp4.12669
27. Burger B, Maffettone PM, Gusev VV, Aitchison CM, Bai Y, Wang X, et al. A mobile robotic chemist. Nature. 2020;583(7815):237-41. doi:10.1038/s41586-020-2442-2
28. Granda JM, Donina L, Dragone V, Long DL, Cronin L. Controlling an organic synthesis robot with machine learning to search for new reactivity. Nature. 2018;559(7714):377-81. doi:10.1038/s41586-018-0307-8
29. Greenhalgh T, Wherton J, Papoutsi C, Lynch J, Hughes G, A'Court C, et al. Beyond adoption: A new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. J Med Internet Res. 2017;19(11). doi:10.2196/jmir.8775
30. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: Update of Medical Research Council guidance. BMJ. 2021;374. doi:10.1136/bmj.n2061